Physician profile
Sarah E Rucker
NPI 1386214476
$2,880.97
in general payments reported to CMS, 2019-2025
29 companies · $1,864 in 2025
The $1,864 reported for 2025 was more than what 94% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $263 · 2023: $41.96 · 2024: $712 · 2025: $1,864.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,003 · Travel and Lodging: $615.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,002.96 |
| Travel and Lodging | $615.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $1,160.98 | 2024-2025 | Synergy Ablation System, Epi-Sense Guided Coagulation System With Visitrax |
| Actelion Pharmaceuticals US, INC. | $202.16 | 2025 | Uptravi, Opsumit |
| Teva Pharmaceuticals USA, INC. | $131.09 | 2024 | Austedo Xr |
| Silk Road Medical, INC. | $129.31 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter, Enroute Transcarotid Stent |
| Neurocrine Biosciences, INC. | $125.00 | 2025 | |
| Philips North America LLC | $114.31 | 2022-2024 | (5091) Amb Mon & Diag Und |
| Novo Nordisk INC | $112.00 | 2025 | Ozempic |
| Amgen INC. | $96.61 | 2024 | Repatha |
| Impulse Dynamics (USA) INC. | $94.39 | 2022 | |
| Pfizer INC. | $93.33 | 2024-2025 | |
| Biogen, INC. | $87.50 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $56.68 | 2023-2024 | Lifevest |
| Kiniksa Pharmaceuticals International, Plc | $49.20 | 2024 | Arcalyst |
| Alnylam Pharmaceuticals INC. | $48.32 | 2025 | Amvuttra |
| Scpharmaceuticals INC. | $42.23 | 2024 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $39.51 | 2024 | Evkeeza |
| Merck Sharp & Dohme LLC | $38.47 | 2024-2025 | Verquvo |
| Cvrx, INC. | $36.72 | 2025 | Barostim Neo System |
| Bayer Healthcare Pharmaceuticals INC. | $25.16 | 2025 | |
| Novartis Pharmaceuticals Corporation | $23.72 | 2025 | |
| Medtronic, INC. | $22.60 | 2022 | |
| Daiichi Sankyo INC. | $20.91 | 2024 | Injectafer |
| Davol INC. | $20.15 | 2025 | Arista |
| Corcept Therapeutics | $19.91 | 2025 | Korlym |
| E.R. Squibb & Sons, L.L.C. | $19.78 | 2025 | Camzyos |
| 3b Medical, INC. | $19.36 | 2024 | Luna |
| Esperion Therapeutics, INC. | $17.61 | 2024 | Nexletol |
| Inspire Medical Systems, INC. | $17.40 | 2025 | Inspire |
| Abbott Laboratories | $16.56 | 2025 | Freestyle Libre 3 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Rucker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.